These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32762989)

  • 21. An EQ-5D-5L Value Set for Ghana Using an Adapted EuroQol Valuation Technology Protocol.
    Addo R; Mulhern B; Norman R; Owusu R; Viney R; Nonvignon J
    Value Health Reg Issues; 2024 Sep; 45():101045. PubMed ID: 39236574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Graczyk K; Niewada M
    Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
    Craig BM; Rand K
    Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testing "Pits" Time Trade-Off: Can Data Quality be Improved by Removing Death From Valuation of Health States?
    Liao M; Yang Z; Rand K; Luo N
    Value Health; 2024 Sep; 27(9):1261-1269. PubMed ID: 38795961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New methods for modelling EQ-5D-5L value sets: An application to English data.
    Feng Y; Devlin NJ; Shah KK; Mulhern B; van Hout B
    Health Econ; 2018 Jan; 27(1):23-38. PubMed ID: 28833854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How different are composite and traditional TTO valuations of severe EQ-5D-5L states?
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA
    Qual Life Res; 2016 Aug; 25(8):2101-8. PubMed ID: 26875190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring health-related quality of life in the general population and Roma communities in Romania: study protocol for two cross-sectional studies.
    Olariu E; Paveliu MS; Baican E; Oluboyede Y; Vale L; Niculescu-Aron IG
    BMJ Open; 2019 Aug; 9(8):e029067. PubMed ID: 31427330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states.
    Norman R; Cronin P; Viney R
    Appl Health Econ Health Policy; 2013 Jun; 11(3):287-98. PubMed ID: 23649892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
    Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valuing the EQ Health and Wellbeing Short Using Time Trade-Off and a Discrete Choice Experiment: A Feasibility Study.
    Mukuria C; Peasgood T; McDool E; Norman R; Rowen D; Brazier J
    Value Health; 2023 Jul; 26(7):1073-1084. PubMed ID: 36805577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EQ-5D-5L Health-State Values for the Mexican Population.
    Gutierrez-Delgado C; Galindo-Suárez RM; Cruz-Santiago C; Shah K; Papadimitropoulos M; Feng Y; Zamora B; Devlin N
    Appl Health Econ Health Policy; 2021 Nov; 19(6):905-914. PubMed ID: 34173957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The EQ-5D-5L valuation study in Korea.
    Kim SH; Ahn J; Ock M; Shin S; Park J; Luo N; Jo MW
    Qual Life Res; 2016 Jul; 25(7):1845-52. PubMed ID: 26961008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
    Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
    Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The EQ-5D-5L Valuation Study in Egypt.
    Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
    Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set.
    Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M
    Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value Set for the EQ-5D-Y-3L in Hungary.
    Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
    Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
    Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EQ-5D-Y Value Set for Germany.
    Kreimeier S; Mott D; Ludwig K; Greiner W;
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating an EQ-5D-Y-3L Value Set for China.
    Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.